

Severe, early onset hypertrophic cardiomyopathy in a family with LEOPARD syndrome

Giuseppe Limongelli¹
Giuseppe Pacileo¹
Maria Giovanna Russo¹
Anna Sarkozy³
Maria Felicetti⁴
Giovanni Di Salvo¹
Carmela Morelli¹
Paolo Calabrò¹
Dario Paladini⁴
Bruno Marino²
Bruno Dallapiccola³
Raffaele Calabrò¹

¹ Chair of Cardiology, Second University of Naples, Monaldi Hospital

² "La Sapienza" University, Department of Pediatrics, Rome, Italy

³ IRCCS-CSS, San Giovanni Rotondo e CSS-Mendel Institute, Rome, Italy

⁴ Department of Gynecology, "Federico II", Naples, Italy

Reprint requests to: Giuseppe Limongelli, MD, PhD
Chair of Cardiology, Monaldi Hospital
Second University of Naples, Naples, Italy
Tel. +39 081 7062852
Fax +39 081 7062683
E-mail: limongelligiuseppe@libero.it

Summary

LEOPARD syndrome (multiple Lentiginos, Electrocardiographic conduction abnormalities, Ocular hypertelorism, Pulmonic stenosis, Abnormal genitalia, Retardation of growth, and sensorineural Deafness) is a rare inherited disease. Mutations in the PTPN11 and RAF-1 genes have been reported in patients with LEOPARD syndrome.

Although the clinical course is generally favourable, a number of sudden cardiac deaths have been reported in association with this syndrome. Patients with hypertrophic cardiomyopathy (HCM) have potentially a higher risk of developing severe cardiac complications during follow-up. Here, we describe a family (mother and daughter) with clinical and molecular diagnosis of LEOPARD syndrome 1 and HCM (mild, non obstructive HCM in the mother; severe, obstructive HCM in the daughter), and we report the prenatal diagnosis of a severe HCM in a fetus at risk for LEOPARD syndrome.

KEY WORDS: prenatal diagnosis; LEOPARD syndrome; hypertrophic cardiomyopathy; natural history.

Introduction

LEOPARD syndrome is an acronym (multiple Lentiginos, Electrocardiographic conduction abnormalities, Ocular hypertelorism, Pulmonic stenosis, Abnormal genitalia, Retardation of growth, and sensorineural Deafness) describing an autosomal dominant disease due to mutations in the RAS-MAPK pathway (1-3). The *PTPN11* gene, encoding the protein tyrosine phosphatase SHP-2, causes the disease in 80% of the patients affected (LEOPARD syndrome type 1) (2). Pandit et al. recently described RAF-1 mutations in 2 out of six patients with LEOPARD syndrome without *PTPN11* mutations (LEOPARD syndrome type 2) (3). Clinical outcome is worse in patients with cardiovascular involvement, and a number of fatal events have been reported in patients affected by hypertrophic cardiomyopathy (HCM) associated with the syndrome (4, 5). Here, we describe a family (mother and daughter) with clinical and molecular diagnosis of LEOPARD syndrome 1 and HCM, and we report the prenatal diagnosis of HCM in a fetus at risk for LEOPARD syndrome.

Case Report

The family pedigree is showed in Figure 1. A 32-year-old woman with LEOPARD syndrome with multiple lentiginos, facial dysmorphism, short stature, and mild, non obstructive HCM (asymmetric left ventricular hypertrophy, with maximal wall thickness of 14 mm at the mid-portion of the posterior interventricular septum, in absence of outflow tract obstruction) was referred to our Department for foetal echocardiography and genetic counselling during her second pregnancy. Her first pregnancy resulted in a daughter (the proband) who was born with a severe form of obstructive HCM, and pulmonary valvar and subvalvar stenosis. She had café au lait spots on her trunk, hypertelorism, broad nasal bridge, pterigium colli, pectus excavatum and short stature. She was administered with beta blockers (7 mg/kg/day) for her cardiomyopathy, but she died suddenly at 2 years of age. Clinical diagnosis of LEOPARD syndrome was confirmed by genetic analysis showing a mutation in exon 13 of the *PTPN11* gene (codon 498), in both mother and daughter.

During the second pregnancy, prenatal scan at 22 weeks of gestation evidenced fetal growth restriction (about 3 weeks), and fetal echocardiography showed a significant hypertrophy of both ventricles (left and right ventricular wall thickness 9mm and 3 mm, respectively) (Figure 2). Systolic function was slightly depressed (ejection fraction measured by biplane Simpson method was 45%), and diastolic function was abnormal.

The parents were counselled by a team of physicians




Figure 1 - Family Pedigree: an Italian kindred with LEOPARD syndrome and hypertrophic cardiomyopathy. Proband is indicated by arrow. Circles indicate females; squares, males; triangle, sex unknown; open symbols, unaffected individuals; filled symbols, individuals affected (by LEOPARD syndrome); symbols with slash are deceased individuals; question mark, unknown clinical status; plus sign, presence of mutation (i.e., PTPN11 mutation); minus sign, absence of mutation.




Figure 2 - Fetal echocardiography showing hypertrophic cardiomyopathy.

(gynaecologists, paediatric cardiologists, psychologists, and geneticists) regarding the clinical manifestations and outcome of LEOPARD syndrome in general and HCM associated with this condition in particular and decided to terminate the pregnancy.

Discussion

HCM is an etiologically heterogeneous condition with intrafamilial and interfamilial variability in the clinical man-

ifestations (8). Natural history of early onset HCM is extremely variable (9, 10). Pedra et al. described prenatal characteristic and postnatal outcome of 33 foetuses with hypertrophic cardiomyopathy (11). Two termination of pregnancy (1 Noonan, 1 sarcomeric hypertrophic cardiomyopathy) were reported. Of note, one patient with severe, biventricular hypertrophy survived the perinatal period, and cardiac hypertrophy resolved by 3 months of age.

HCM is the most common defect in patients with LEOPARD syndrome (about 70% of the cases) (6). Long-term prognosis seems benign in LEOPARD syndrome patients with only mild cardiac abnormalities (6, 7). On the other hand, patients with HCM may develop arrhythmias and other life-threatening complications (6, 7). The phenotype (a severe, obstructive left ventricular hypertrophy) may represent a risk factor for adverse clinical outcome (sudden death; as in the present case) in patients with LEOPARD syndrome and HCM. In addition, the genotype may represent a potential risk factor of adverse event in selected patients. We have recently reported 2 patients with an early onset obstructive HCM, associated with a high risk of heart failure and cardiac events. We showed a specific mutation in exon 13 of the PTPN11 gene (codon 510) (7). Of note, in the present report both the mother and her daughter had a mutation in exon 13 of the PTPN11 gene (codon 498). However, intrafamilial variability is clear in the present report (since the mother had a mild form of HCM, while the first daughter and the foetus showed a severe, early onset hypertrophic disease), representing a strong limitation to the potential use of the genotype (i.e. mutations in exon 13) as clinical predictor of malignant events in patients with HCM and LEOPARD syndrome.

In conclusion, HCM significantly worsen the prognosis in LEOPARD syndrome. However, lacking large population studies on HCM associated to the rare LEOPARD syndrome, the clinical and genetic heterogeneity of the disease warrant particular attention, especially in prenatal counselling, which should involve a multidisciplinary and experienced team (gynecologist, cardiologist, geneticists, and psychologist).

References

- Voron DA, Hatfield HH, Kalkhoff RK. Multiple lentiginos syndrome. Case report and review of the literature. *Am J Med* 1976;60:447-456.
- Digilio MC, Conti E, Sarkozy A, Mingarelli R, Dottorini T, Marino B, Pizzuti A, Dallapiccola B. Grouping of multiple-lentiginos/LEOPARD and Noonan syndromes on the PTPN11 gene. *Am J Hum Genet* 2002;71:389-394.
- Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, Pogna EA, Schackwitz W, Ustaszewska A, Landstrom A, Bos JM, Ommen SR, Esposito G, Lepri F, Faul C, Mundel P, Lopez Sigüero JP, Tenconi R, Selicorni A, Rossi C, Mazzanti L, Torrente I, Marino B, Digilio MC, Zampino G, Ackerman MJ, Dallapiccola B, Tartaglia M, Gelb BD. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. *Nat Genet* 2007;39(8):1007-12.
- Limongelli G, Pacileo G, Calabro R. Is sudden cardiac death predictable in LEOPARD syndrome? *Cardiol Young* 2006;16:599-601.

5. Woywodt A, Welzel J, Haase H, Duerholz A, Wiegand U, Potratz J, Sheikhzadeh A. Cardiomyopathic Lentiginosis/LEOPARD syndrome presenting as sudden cardiac arrest. *Chest* 1998;113:1415-1417.
 6. Limongelli G, Pacileo G, Marino B, Digilio MC, Sarkozy A, Elliott P, Versacci P, Calabro P, De Zorzi A, Di Salvo G, Syrris P, Patton M, McKenna WJ, Dallapiccola B, Calabro R. Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome. *Am J Cardiol.* 2007 15;100:736-41.
 7. Limongelli G, Sarkozy A, Pacileo G, Calabro' P, Digilio MC, Maddaloni V, Gagliardi G, Di Salvo G, Iacomino M, Marino B, Dallapiccola B, Calabro' R. Genotype-phenotype analysis and natural history of left ventricular hypertrophy in LEOPARD syndrome. *Am J Med Gen A*; 2008;146: 620-8.
 8. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED; Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. American College of Cardiology/Euro-pean Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. *J Am Coll Cardiol.* 2003;42:1687-713.
 9. Nugent AW, Daubeney PE, Chondros P, Carlin JB, Colan SD, Cheung M, Davis AM, Chow CW, Weintraub RG; National Australian Childhood Cardiomyopathy Study. Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. *Circulation.* 2005;112:1332-8.
 10. Maron BJ, Tajik AJ, Ruttenberg HD, Graham TP, Atwood GF, Victorica BE, Lie JT, Roberts WC. Hypertrophic cardiomyopathy in infants: clinical features and natural history. *Circulation.* 1982;65:7-17.
 11. Pedra SR, Smallhorn JF, Ryan G, Chitayat D, Taylor GP, Khan R, Abdoell M, Hornberger LK. Fetal cardiomyopathies: pathogenic mechanisms, hemodynamic findings, and clinical outcome. *Circulation* 2002; 106:585-91.
- No conflict of interest declared.